Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.72 |
| ▸ | BCR | P11274 | 9/20 | 0.72 |
| ▸ | PRKCA | P17252 | 3/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29726383 | 1.00 | ABL1 (0.72) | ABL1BCRPRKCALCKPDGFRA | |
| SCHEMBL13157373 | 0.88 | ABL1 (0.75) | ABL1BCRPRKCALCKPDGFRA | |
| SCHEMBL14041907 | 0.86 | ABL1 (0.72) | ABL1BCRPRKCALCKPDGFRA | |
| SCHEMBL2575958 | 0.86 | ABL1 (0.78) | ABL1BCRPRKCALCKPDGFRA | |
| SCHEMBL14041906 | 0.85 | ABL1 (0.78) | ABL1BCRPRKCALCKPDGFRA | |
| SCHEMBL3099819 | 0.84 | ABL1 (0.69) | ABL1BCRPRKCALCKPDGFRA | |
| SCHEMBL13181932 | 0.84 | ABL1 (0.54) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL29366999 | 0.84 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL2392 | 0.84 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL29555505 | 0.84 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725005-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230159514-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-10906896-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200031819-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-9828370-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-20160311816-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| CN-101456841-B | Amide derivative and medicine | NIPPON SHINYAKU CO LTD | 2012-01-25 | — | — | CN | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| CN-101456841-A | Amide derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 2009-06-17 | — | — | CN | disclosed |
| US-7494997-B2 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| WO-2008058037-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-15 | — | — | WO | disclosed |
| CN-100343237-C | Amide derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 2007-10-17 | — | — | CN | disclosed |
| CN-1898208-A | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | CN | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-20060014742-A1 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| CN-1678590-A | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2005-10-05 | — | — | CN | disclosed |
| EP-1533304-A1 | AMIDE DERIVATIVE | Nippon Shinyaku Co., Ltd. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014742-A1 | Amide derivative | ABL1, ABL2, BCR | ABL1 1/4885BCR 3/4885PRKCA 323/4885 |
| US-20200031819-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | ABL1 25/4885BCR 545/4885PRKCA 26/4885 |
| US-20160311816-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | ABL1 25/4885BCR 545/4885PRKCA 26/4885 |
| US-10906896-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | ABL1 25/4885BCR 545/4885PRKCA 26/4885 |
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | ABL1 2/4885BCR 3/4885PRKCA 376/4885 |
| US-20230159514-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | ABL1 25/4885BCR 545/4885PRKCA 26/4885 |
| US-11725005-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | ABL1 25/4885BCR 545/4885PRKCA 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.